Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
Journal: HIV Medicine
Year: 2017

We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.